BIOMARIN PHARMACEUTICAL INC

Form 4

January 03, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

OMB APPROVAL

burden hours per response...

if no longer subject to Section 16. Form 4 or

Check this box

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person ** Swiedler Stuart J			2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			BIOMARIN PHARMACEUTICAL INC [BMRN]	(Check all applicable)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Director 10% Owner Street Control of the control o		
C/O BIOMAR	RIN		01/02/2008	below) below) SVP, Clinical Affairs		
PHARMACE	UTICAL I	NC., 105		5 v1 , Clinical Attails		
DIGITAL DR	IVE					
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
			Filed(Month/Day/Year)	Applicable Line)		
				X Form filed by One Reporting Person Form filed by More than One Reporting		
NOVATO, CA	A 94949			Person		

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secui	rities Acquii	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securit or Dispos (Instr. 3, 4	ed of (5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/02/2008(1)	01/02/2008	M	12,500	A	\$ 6.13	22,500	D	
Common Stock	01/02/2008(1)	01/02/2008	S	642	D	\$ 35.96	21,858	D	
Common Stock	01/02/2008(1)	01/02/2008	S	100	D	\$ 35.97	21,758	D	
Common Stock	01/02/2008(1)	01/02/2008	S	500	D	\$ 35.99	21,258	D	
	01/02/2008(1)	01/02/2008	S	750	D	\$ 36	20,508	D	

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	01/02/2008(1)	01/02/2008	S	400	D	\$ 36.0001	20,108	D
Common Stock	01/02/2008(1)	01/02/2008	S	100	D	\$ 36.0025	20,008	D
Common Stock	01/02/2008(1)	01/02/2008	S	8	D	\$ 36.0501	20,000	D
Common Stock	01/02/2008(1)	01/02/2008	S	150	D	\$ 36.1	19,850	D
Common Stock	01/02/2008(1)	01/02/2008	S	1,100	D	\$ 36.11	18,750	D
Common Stock	01/02/2008(1)	01/02/2008	S	1,250	D	\$ 36.1401	17,500	D
Common Stock	01/02/2008(1)	01/02/2008	S	1,250	D	\$ 36.1801	16,250	D
Common Stock	01/02/2008(1)	01/02/2008	S	470	D	\$ 36.3	15,780	D
Common Stock	01/02/2008(1)	01/02/2008	S	740	D	\$ 36.31	15,040	D
Common Stock	01/02/2008(1)	01/02/2008	S	40	D	\$ 36.32	15,000	D
Common Stock	01/02/2008(1)	01/02/2008	S	209	D	\$ 36.48	14,791	D
Common Stock	01/02/2008(1)	01/02/2008	S	300	D	\$ 36.49	14,491	D
Common Stock	01/02/2008(1)	01/02/2008	S	441	D	\$ 36.5	14,050	D
Common Stock	01/02/2008(1)	01/02/2008	S	300	D	\$ 36.51	13,750	D
Common Stock	01/02/2008(1)	01/02/2008	S	1,250	D	\$ 35.28	12,500	D
Common Stock	01/02/2008(1)	01/02/2008	S	1,250	D	\$ 36.0301	11,250	D
Common Stock	01/02/2008(1)	01/02/2008	S	750	D	\$ 36.31	10,500	D
Common Stock	01/02/2008(1)	01/02/2008	S	200	D	\$ 36.35	10,300	D
Common Stock	01/02/2008(1)	01/02/2008	S	300	D	\$ 36.38	10,000	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of tiorDerivative Expiration Date Securities (Month/Day/Year) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 6.13	01/02/2008(1)	01/02/2008	M	12,500	07/07/2005(2)	01/06/2015	Common Stock	12,500

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Swiedler Stuart J C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			SVP, Clinical Affairs				

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
- (2) Original option grant vested 6/48ths on 7/7/2005 and 1/48th on the 7th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3